PolyNovo Limited (CALZF)
OTCMKTS
· Delayed Price · Currency is USD
0.9420
+0.0004 (0.04%)
May 9, 2025, 4:00 PM EDT
PolyNovo Revenue
PolyNovo had revenue of 59.54M AUD in the half year ending December 31, 2024, with 102.62% growth. This brings the company's revenue in the last twelve months to 115.58M, up 38.47% year-over-year. In the fiscal year ending June 30, 2024, PolyNovo had annual revenue of 103.23M with 57.20% growth.
Revenue (ttm)
115.58M AUD
Revenue Growth
+38.47%
P/S Ratio
10.28
Revenue / Employee
455.03K AUD
Employees
254
Market Cap
735.45M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 103.23M | 37.56M | 57.20% |
| Jun 30, 2023 | 65.67M | 23.78M | 56.76% |
| Jun 30, 2022 | 41.89M | 12.55M | 42.78% |
| Jun 30, 2021 | 29.34M | 7.15M | 32.19% |
| Jun 30, 2020 | 22.19M | 8.15M | 58.03% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
PolyNovo News
- 2 months ago - PolyNovo chief executive steps down after dispute with chairman - The Australian Financial Review
- 2 months ago - David Williams says he makes no apologies for ‘aggressive’ style - The Australian Financial Review
- 9 months ago - Polynovo Ltd (CALZF) (Q4 2024) Earnings Call Transcript Highlights: Record Revenue and ... - GuruFocus